Literature DB >> 15130891

A beneficial role of cardiac P2X4 receptors in heart failure: rescue of the calsequestrin overexpression model of cardiomyopathy.

Alexander Yang1, Dimitry Sonin, Larry Jones, William H Barry, Bruce T Liang.   

Abstract

The P2X4 purinergic receptor (P2X4R) is a ligand-gated ion channel. Its activation by extracellular ATP results in Ca2+ influx. Transgenic cardiac overexpression of the human P2X4 receptor showed an in vitro phenotype of enhanced basal contractility. The objective here was to determine the in vivo cardiac physiological role of this receptor. Specifically, we tested the hypothesis that this receptor plays an important role in modulating heart failure progression. Transgenic cardiac overexpression of canine calsequestrin (CSQ) showed hypertrophy, heart failure, and premature death. Crossing the P2X4R mouse with the CSQ mouse more than doubled the lifespan (182 +/- 91 days for the binary CSQ/P2X4R mouse, n = 35) of the CSQ mouse (71.3 +/- 25.4 days, n = 50, P < 0.0001). The prolonged survival in the binary CSQ/P2X4R mouse was associated with an improved left ventricular weight-to-body weight ratio and a restored beta-adrenergic responsiveness. The beneficial phenotype of the binary mouse was not associated with any downregulation of the CSQ level but correlated with improved left ventricular developed pressure and +/-dP/dt. The enhanced cardiac performance was manifested in young binary animals and persisted in older animals. The increased contractility likely underlies the survival benefit from P2X4 receptor overexpression. An increased expression or activation of this receptor may represent a new approach in the therapy of heart failure.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15130891     DOI: 10.1152/ajpheart.00079.2004

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  24 in total

Review 1.  Molecular and functional properties of P2X receptors--recent progress and persisting challenges.

Authors:  Karina Kaczmarek-Hájek; Eva Lörinczi; Ralf Hausmann; Annette Nicke
Journal:  Purinergic Signal       Date:  2012-05-01       Impact factor: 3.765

2.  A neoceptor approach to unraveling microscopic interactions between the human A2A adenosine receptor and its agonists.

Authors:  Kenneth A Jacobson; Michihiro Ohno; Heng T Duong; Soo-Kyung Kim; Susanna Tchilibon; Michal Cesnek; Antonín Holý; Zhan-Guo Gao
Journal:  Chem Biol       Date:  2005-02

Review 3.  Cardiac purinergic signalling in health and disease.

Authors:  Geoffrey Burnstock; Amir Pelleg
Journal:  Purinergic Signal       Date:  2014-12-20       Impact factor: 3.765

4.  Microarray analysis of active cardiac remodeling genes in a familial hypertrophic cardiomyopathy mouse model rescued by a phospholamban knockout.

Authors:  Sudarsan Rajan; James R Pena; Anil G Jegga; Bruce J Aronow; Beata M Wolska; David F Wieczorek
Journal:  Physiol Genomics       Date:  2013-06-25       Impact factor: 3.107

5.  P2X purinergic receptor-mediated ionic current in cardiac myocytes of calsequestrin model of cardiomyopathy: implications for the treatment of heart failure.

Authors:  Jian-Bing Shen; Chunxia Cronin; Dmitry Sonin; Bhalchandra V Joshi; Maria Gongora Nieto; David Harrison; Kenneth A Jacobson; Bruce T Liang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-10-13       Impact factor: 4.733

6.  Inhibiting the P2X4 Receptor Suppresses Prostate Cancer Growth In Vitro and In Vivo, Suggesting a Potential Clinical Target.

Authors:  Jiepei He; Yuhan Zhou; Hector M Arredondo Carrera; Alexandria Sprules; Ramona Neagu; Sayyed Amin Zarkesh; Colby Eaton; Jian Luo; Alison Gartland; Ning Wang
Journal:  Cells       Date:  2020-11-20       Impact factor: 6.600

7.  P2 purinergic receptor mRNA in rat and human sinoatrial node and other heart regions.

Authors:  Hanny Musa; James O Tellez; Natalie J Chandler; Ian D Greener; Michał Maczewski; Urszula Mackiewicz; Andrzej Beresewicz; Peter Molenaar; Mark R Boyett; Halina Dobrzynski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-02-21       Impact factor: 3.000

8.  Reversal of cardiac myocyte dysfunction as a unique mechanism of rescue by P2X4 receptors in cardiomyopathy.

Authors:  Jian-Bing Shen; Robin Shutt; Mariela Agosto; Achilles Pappano; Bruce T Liang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-02-06       Impact factor: 4.733

9.  Facilitated maturation of Ca2+ handling properties of human embryonic stem cell-derived cardiomyocytes by calsequestrin expression.

Authors:  Jing Liu; Deborah K Lieu; Chung Wah Siu; Ji-Dong Fu; Hung-Fat Tse; Ronald A Li
Journal:  Am J Physiol Cell Physiol       Date:  2009-04-08       Impact factor: 4.249

10.  The therapeutic effect of 2-cyclohexylthio-AMP in heart failure.

Authors:  Siyuan Zhou; Tiehong Yang; Kenneth A Jacobson; Bruce T Liang
Journal:  J Cardiovasc Pharmacol       Date:  2013-06       Impact factor: 3.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.